Zheng-Sheng Lai
Overview
Explore the profile of Zheng-Sheng Lai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
17
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang J, Hung C, Liou Y, Liu C, Yeh K, Wang K, et al.
Elife
. 2024 May;
12.
PMID: 38752723
A causal relationship exists among the aging process, organ decay and disfunction, and the occurrence of various diseases including cancer. A genetically engineered mouse model, termed or (K74R), carrying mutation...
2.
Fu Y, Ou D, Yang Y, Su K, Chen C, Tien H, et al.
Cancer Gene Ther
. 2021 Jun;
29(6):784-792.
PMID: 34117374
Cabozantinib is a potent tyrosine kinase inhibitor with multiple targets including MET, VEGFR2, RET, KIT, and FLT3. Cabozantinib is widely used for the treatment of medullary thyroid cancer and renal...
3.
Lai Z, Yeh T, Chou Y, Hsu T, Lu C, Kung F, et al.
Eur J Med Chem
. 2020 Oct;
209:112938.
PMID: 33109398
Reactivation of fetal hemoglobin (HbF) expression by therapeutic agents has been suggested as an alternative treatment to modulate anemia and the related symptoms of severe β-thalassemia and sickle cell disease...
4.
Chou Y, Chen R, Lai Z, Song J, Chao Y, Shen C
Mol Cell Biol
. 2015 May;
35(14):2541-53.
PMID: 25986606
Pharmacological induction of the fetal γ globin gene and the consequent formation of HbF (α2/γ2) in adult erythroid cells are one feasible therapeutic strategy for sickle cell disease (SCD) and...